DYSFUNCTION OF RENAL SELF-DEFENCE MECHANISMS IN CHRONIC GLOMERULONEPHRITIS


Cite item

Full Text

Abstract

Mechanisms of self-defense of renal tissue in chronic glomerulonephritis are discussed. Anti-inflammatory factors as an perspective therapeutic approach in chronic kidney disease are reviewed

References

  1. . Kitamura M. TGF-β as an endogenous defender against macrophage-triggered stromelysin gene expression in the glomerulus. J Immunol.1998; 160: 5163-5168
  2. . Sedor J.R., Nakazato Y., Konieczkowski M. Interleukin-1 and the mesangial cell. Kidney Int.1992; 41: 595-599
  3. . Arend W.P. Interleukin-1 receptor antagonist: A new member of the interleukin-1 family. J Clin Invest. 1991; 88: 1445-1451
  4. . Tam F.W.K., Smith J., Cashman S.J. et al. Glomerular expression of interleukin receptor antagonist and interleukin-1β genes in antibody-mediated glomerulonephritis. Am J Pathol. 1994; 145: 126-136
  5. . Arene W.P., Welgus H.G., Thompson R.C., Eisenberg S.P. Biologic properties of recombinant human monocyte-derivated interleukin-1 receptor antagonist. J Clin Invest. 1990; 85: 1694-1697
  6. . Luttropp K., Lindholm B., Carrero J.J. et al. Genetics/genomics in chronic kidney disease - towards personalized medicine? Seminars in Dialysis. 2009; 22(4): 417-422
  7. . Liu Z., Yang J., Chen Z. et al. Gene polymorphism in IL-1 receptor antagonist affects its production by monocytes in IgA nephropathy and Henoch-Schonlein nephritis. Chin Med J. 2001; 114(12): 1313-1316
  8. . Buraczynska M., Ksiazek P., Kubit P., Zaluska W. Interleukin-1 receptor antagonist gene polymorphism affects the progression of chronic renal failure. Cytokine. 2006; 36 (3-4): 167-172
  9. . Hahn W.H., Cho B.S., Kim S.K., Kang S. Interleukin-1 cluster gene polymorphism in childhood IgA nephropathy. Pediatr Nephrol. 2009; 24(7):1329-1336
  10. . Rauta V., Teppo A-M., Tornroth T. et al. Lower urinary interleukin-1 receptor antagonist excretion in IgA nephropathy than in Henoch-Schonlein nephritis. Nephrol Dial Transplant. 2003; 18: 1785-1791
  11. . Zwiech R., Kacprzyk F., Szuflet A., Nowicki M. Prognostic values of serum concentration and urinary excretion of interleukin-1 receptor antagonist and tumor necrosis factor receptors type I and II in patients with IgA nephropathy. Pol Arch Med Wewn.2005; 113(4): 326-333
  12. . Sturfelt G., Roux-Lombard P., Wollheim F.A., Dayer J-M. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. British J Rheumatology. 1997;36:1283-1289
  13. . Chen A., Sheu L.F., Chou W.Y. et al. Interleukin-1 receptor antagonist modulates the progression of a spontaneously occurring IgA nephropaty in mice. Am J Kidney Dis.1997; 30(5): 693-702
  14. . Nikolic-Paterson D.J., Lan H.Y., Hill P.A. et al. Supression of experimental glomerulonephritis by the interleukin-1 receptor antagonist: Inhibition of intercellular adhesion molecule-1 expression. J Am Soc Nephrol. 1994; 4: 1695-1700
  15. . Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92: 827-839.
  16. . Wojtovicz-Praga S.M., Dickson R.M., Hawkins M.J. et al. Matrix metalloproteinases inhibitors. Invest New Drugs 1997; 15: 61-75.
  17. . Marti H.P. Role of matrix metalloproteinases in the progression of renal lesion. Press Med 2000; 29: 811-817.
  18. . Бобкова И.Н., Козловская Л.В., Ли О.А. Матриксные металлопротеиназы в патогенезе острых и хронических заболеваний почек. Нефрология и диализ. 2008; 2(10):105-111.
  19. . Ли О.А., Бобкова И.Н., Козловская Л.В. Клиническое значение определения матриксных металлопротеиназ и их ингибиторов в моче больных хроническим гломерулонефритом. Терапевтический архив. 2009; № 8: 10-14
  20. . Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy - review of a new approach. Pharmacol Rev.2003; 55:241-269
  21. . Fouquerbay B., Boutard V., Phillipe C. et al. Mesangial cell-derived interleukin-10 modulates mesangial cell response to lipipolysaccharide. Am J Pathol.1995;147:176-182
  22. . Stenvinkel P., Ketteler M., Jonson J.R. et al. IL-10, Il-6 and TNF-α: Central factors in the altered cytokine network of uremia - The good, the bad, and the ugly. Kidney Int. 2005;Vol 67: 1216-1233
  23. . Wanidvoranun C., Strober W. Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol. 1993;151:6853-6861
  24. . Chan R.W., Lai F.M., Li E.K. et al. Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology. 2006; 45: 951-957
  25. . Симбирцев А.С. Цитокины - новая система регуляции защитных реакций организма. Цитокины и воспаление. 2002; 1(1): 9-16 .
  26. de Waal Malefyt R., Abrams J. et al. Interleukin-10 inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991; 174: 1209-1220
  27. . Olszina D.P., Pajkrt D., Lauw F.N., van Deventer S.J. Interleukin-10 inhibits the release of CC chemokines during human endotoxemia. J Infect Dis.2000; 181: 613-620
  28. . Kuga S., Otsuka T., Niiro H. et al. Supression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. Exp Hematol. 1996; 24: 151-157
  29. . Fouqueray B., Suberville S., Isaka Y. et al. Reduction of proteinuria in anti-glomerular basement membrane nephritis by interleukin-10 (IL-10) gene transfer. J Am Soc Nephrol.1996;7:1698-1701
  30. . Tipping P.G., Kitching A.R., Huang X.R. et al. Immune modulation with interleukin-4 and interleukin-10 prevent crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol. 1997;27:530-537
  31. . Kitching A.R., Katerelos M., Mudge S.J. et al. Interleukin-10 inhibits experimental mesangial proliferative glomerulonephritis. Clin Exp Immunol. 2002; 128:36-43
  32. . Coelho S.N., Saleem S., Konieczny B.T. et al. Immunologic determinants of susceptibility to experimental glomerulonephritis: role of cellular immunity. Kidney Int. 1997; 51: 646-652
  33. . Cairns L.S., Phelps R.G., Bowie L. et al. The fine specificity and cytoline profile of T-helper cells responsive to the alfa3 chain of type IV collagen in Goodpasture's disease. J Am Soc Nephrol. 2003; 14: 2801-2812
  34. . Masutani K., Tokumoto M., Nakashima H. Strong polarization toward Th1 immune response in ANCA-associated glomerulonephritis. Clin Nephrol. 2003; 59: 395-405
  35. . Tipping P.G., Kitching A.R. Th1 and Th2:what's new? Clin and Exp Immunol. 2005; 142: 207-215
  36. . Romagnani S. Biology of human Th1 and Th2 cells. J Clin Immunol. 1995;15:121-129
  37. . Wang Y.P., Kairaitis L., Tay Y.C. et al. Reconstitution of CD4+ T cells protects renal injury in SCID mice with adriamycin nephropathy (abstract). J Am Soc Nephrol. 2001; 12: 644
  38. . Pandiyan P., Zheng L., Ishihara S. et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007: 8:1353-1362
  39. . Scheffold A., Murphy K.M., Hofer T. Competition for cytokines: T(reg) cells take all. Nat Immunol. 2007; 8: 1285-1287
  40. . Taams L.S., van Amelsfort J.M., Tiemessen M.M. et al. Modulation of monocyte/macrophage function by human CD4+/CD25+ regulatory T cells. Hum Immunol. 2005; 66: 222-230
  41. . Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci. 2008; 13: 453-461
  42. . Wang Y. Wang Y.P, Zheng G. et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 2007; 72: 290-299
  43. . Mosser D.M. The many faces of macrophage activation. J Leukoc Biol. 2003; 73: 209-212
  44. . Wilson H.M., Walbaum D., Rees A.J. Macrophages and the kidney. Curr Opin Nephrol Hypertens. 2004; 13: 285-290
  45. . Papayianni A., Serhan C.N., Philips M.L. et al. Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 1995; 47: 1295-1302
  46. . Claria J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interaction. Proc Natl Acad Sci USA. 1995; 92:9475
  47. . Conrad D.J., Kuhn H., Mulkins M. et al. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci USA. 1992; 89: 217-221
  48. . Brinckmann R., Topp M.S., Zalan I. et al. Regulation of 15-lipoxygenase expression in lung epithelial cells by interleukin-4. Biochem J. 1996; 318: 305-312
  49. . McMahon B., Mitchell S., Brady H.R., Godson C. Lipoxins: Revelation on resolution. Trends Pharmacol Sci. 2001; 8: 391-395
  50. . Colgan S.P., Serhan C.N., Parcos C.A. et al. LipoxinA4 modulates transmigration of human neutrophils across intestinal epithelial monolaeyrs. J Clin Invest. 1993; 92: 75-82
  51. . Ohse T., Ota T., Kieran N. et al. Modulation of interferon-induced genes by lipoxin analogue in anti-glomerular basement membrane nephritis. J Am Soc Nephrol. 2004; 15: 919-927
  52. . Godson C., Mitchell S., Harvey K. et al. Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol. 2000; 164: 1663-1667
  53. . McMahon B., Mitchell D., Shattock R. et al. Lipoxin, leukotriene and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. 2002; 16: 1817-1819
  54. . Fierro I.M., Kutok J.L., Serhan C.N. Novel lipid mediator regulators of endothelial cell proliferation and migration: Aspirin-triggered-15R-lipoxin A4 and lipoxin A4. J Pharmacol Exp Ther. 2002; 300: 385-392
  55. . Katoh T., Takahashi K., DeBoer D.K. et al. Renal hemodynamic actions of lipoxins in rats: A comparative physiological study. 1992; Am J Physiol; 263: 436-442 .
  56. Wu S-H., Liao P-Y., Yin P-L. et al. Elevated expression of 15-lipoxigenase and lipoxin A4 in children with acyte poststreptococcal glomerulonephritis. An J Pathol. 2009; 174: 115-122
  57. . Boutet P., Bureau F., Dengand G., Lekeux P. Inbalance between lipoxin A4 and leukotriene B4 in chronic mastitis-affected cows. J Dairy Sci. 2003; 86: 3430-3439 .
  58. Wu S-H., Liao P-Y., Yin P-L. et al. Inverse temporal changes of lipoxin A4 and leukitrienes in children with Henoch-Schonlein purpura. Prostaglandins, Leukotrienes and essential fatty acids. 80(4): 177-183 .
  59. Beck F-X., Neuhofer W., Muller E. Molecular chaperones in the kidney: distribution, putative roles and regulation. An J Phy siol Renal Physiol. 2000; 279: 203-215
  60. . Aufricht C., Lu E., Thulin G. et al. ATP releases HSP72 from protein aggregates after renal ischemia. Am J Physiol Renal Physiol. 1998; 274: 268-274
  61. . Cowley B.D., Gudapaty S. Temporal alterations in regional gene expression after nephrotoxic renal injury. J Lab Clin Med. 1995; 125: 187-199
  62. . Harrison E.M., Sharpe E., Bellamy C.O. et al. Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury. Am J Physiol Renal Physiol.2008; 295:397-405
  63. . Venkataseshan V.S., Marquet E. Heat shock protein 72/73 in normal and diseased kidneys. Nephron. 1996; 73:442-449 .
  64. Mehlen P, Hickey E., Weber L.A., Arrigo A.P. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generated a protection against TNFα in NIH-3T3-ras cells. Biochem Biophys Res Commun. 1997; 241: 187-192
  65. . Smoyer W.E., Gupta A., Mundel P. et al. Altered expression of glomerular heat shock protein 27 in experimental nephrotic syndrome. J Clin Invest. 1996; 97: 2697-2704
  66. . Welch W.J. Mammalian stress response: Cell physiology, structure/function of stress proteins, and implication for medicine and disease. Physiol Rev.1992;72:1063-1081
  67. . Multhoff G., Hightower L.E. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones. 1996; 1: 167-176
  68. . Kaufmann S.H. Heat shock protein and the immune response. Immunol Todey. 1990; 11: 129-136
  69. . Lydyard P.M., van Eden W. Heat shock proteis: immunity and immunipathology. Immunol Todey. 1990; 11: 228-229
  70. . Jorgensen C., Gedon E., Jaquet C., Sany J. Gastric administration of recombinant 65kDa heat shock protein delays the severi of type II collagen induced arthritis in mice. J Rheumatol. 1998; 25: 763-767
  71. . Trieb К., <http://www3.interscience.wiley.com/journal/118980426/abstract?CRETRY=1&SRETRY=0>Blahovec H., Margreiter R. et al. Heat shock protein expression in the transplanted human kidney. Transplant International. 2005; 14(5): 281-286
  72. . Мухин Н.А., Ляшко В.Н., Маргулис Б.А. и др. Амилоидоз и антитела к белкам теплового шока. Терапевтический архив 1992; 64(5): 79-82
  73. . van Eden W., Tholet J.E.R., van der Zee R. et al. Cloning of the mycobacterial epitope recognized by T lymphocyte in adjuvant arthritis. Nature. 1988; 331:171-173
  74. . Anderton S.M., van der Zee R., Prakken B. et al. Activation of T cells recognizing self 60-kDa heat shock protein can protect against experimental arthritis. J Exp Med. 1995; 181: 943-952
  75. . Paul A.G.A., van Kooten P.J.S., van Eden W., van der Zee R. Highly autoproliferative T cells specific for 60-kDa heat shock protein produce IL-4/IL-10 and IFN-γ and are protective in adjuvant arthritis.J Immunol. 2000; 165: 7270-7277
  76. . Birnbaum G., Kotilinek L., Miller S.D. et al. Heat shock protein s and experimental autoimmune encephalomyelitis . II: environmental infection and extra-neuraxaial inflammation after the course of chronic relapsing encephalomyelitis . J Neuroimmunol. 1998; 90: 149-161
  77. . Dodd S.M., Martin J.E., Swash M., Mather K. Expression of heat shock protein epitopes in renal disease. Clinical Nephrology. 1993; 39(5): 239-244

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies